For the Q2 2026 reporting period, analysts expect Cabaletta Bio to post a loss of $0.37 per share on zero revenue, while the stock currently trades near $2.67 against a consensus price target of $14.83.
The primary story for investors remains the clinical progress of lead CAR-T candidate rese-cel (CABA-201), specifically focused on durability and safety data from preconditioning-free dosing cohorts in the RESET autoimmune program.
Supporting this focus, the company is advancing its pivotal myositis trial to support a planned 2027 regulatory submission and recently expanded its manufacturing capacity through a 10-year agreement with Cellares. Furthermore, a $150 million financing round completed in May 2026 has extended the company's cash runway into mid-2027.